Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729157 · ClinicalTrials.gov registry record · Phase 2
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00729157: Completed Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma, sponsored by National Cancer Institute (NCI).
NCT00729157 is a Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, roughly in line with the 42-participant average among 3 other Recurrent Thyroid Gland Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00729157, a Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor and by carrying tumor-killing substances directly to thyroid cancer cells.
Primary Outcome
Progression-free survival to determine the 6-month progression-free-survival (PFS) rate
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- RADIATION Fludeoxyglucose F-18
- OTHER Pharmacological Study
- BIOLOGICAL Ziv-Aflibercept
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT00729157 record still lists
NCT00729157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, roughly in line with the 42-participant average among 3 other Recurrent Thyroid Gland Carcinoma trials with a reported enrollment target.
The record links to 5 conditions, with Recurrent Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT00729157 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00729157 about?
NCT00729157 is a clinical study titled "Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy". This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor and by carrying tumor-killing subst...
What is the current status of trial NCT00729157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2008-08. Estimated completion is 2012-11.
What conditions does trial NCT00729157 study?
This clinical trial studies the following conditions: Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma.
What interventions are being tested in trial NCT00729157?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fludeoxyglucose F-18 (RADIATION), Pharmacological Study (OTHER), Ziv-Aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00729157?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00729157 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia